# A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

> clinical trial · VERIFIED · 2026-07-14

Status: COMPLETED · Sponsor: R-Pharm · Condition: Head and Neck Squamous Cell Carcinoma

- Company: R-Pharm
- Sector: Head and Neck Squamous Cell Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT07435324

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.